Rebecca Araujo

Urban Health Today

A study being presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting investigated how the use of the fibroblast activation protein (FAP) inhibitor PET tracer [68Ga]Ga-FAPI-46 can inform clinical management of peritoneal metastases from colorectal cancer (PM-CRC) compared with standard-of-care imaging (SCI).The retrospective study included data from 43 patients with suspected PM-CRC. Participants underwent SCI, fluorodeoxyglucose F18 (FDG) PET/CT, and [68Ga]Ga-FAPI-46 PET/CT. The researchers compared standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) of PM, lymph node, bone, and visceral metastases between the imaging modalities. Additionally, they calculated peritoneal cancer index (PCI) scores for each modality and assessed how these informed clinical management in these patients.Of the included patients, 16 had a diffuse-type PM, 21 had a nodular-type PM, and six had no PM (true negatives).In key regions, [68Ga]Ga-FAPI-46 PET/CT outperformed FDG PET/CT, achieving significantly higher SUVmax (6.23 vs 4.27, P&lt;0.01) and TBR values (4.57 vs 1.30; P&lt;0.01). The PCI compliance rate for [68Ga]Ga-FAPI-46 PET/CT exceeded 80% across all 13 regions.Additionally, [68Ga]Ga-FAPI-46 PET/CT demonstrated a 100% patient-based sensitivity for detecting PM-CRC. The patient-based sensitivities for FDG PET/CT and SCI were 92% and 86%, respectively. [68Ga]Ga-FAPI-46 PET/CT showed a 67% specificity and 95% accuracy.Use of [68Ga]Ga-FAPI-46 PET/CT led to different PCI scores compared with FDG PET/CT and SCI in 72% and 91% of patients, respectively. Compared to FDG PET/CT, a larger disease extent of peritoneal involvement and increased distant metastases detected via [68Ga]Ga-FAPI-46 PET/CT led to treatment modifications in 44% of cases. When compared to SCI, peritoneal involvement and distant metastases detected by [68Ga]Ga-FAPI-46 PET/CT led to modifications in 63% of treatment plants.The authors noted that [68Ga]Ga-FAPI-46 PET/CT demonstrated particular efficacy for detecting &ldquo;lesions located in challenging sites such as the periphery of the diaphragm, hepatic ligaments (including the falciform and coronary ligaments), the gallbladder fossa, and the omentum.&rdquo;
<div class="post-references"><h3>References</h3>Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting. <a href="https://jnm.snmjournals.org/content/66/supplement_1/251655" target="_blank" rel="noopener">Abstract No. 251655</a>.
</div>

Barry Greenberg, PhD

Monique Nugent, MD, MPH

Van Ta Park, PhD, MPH

Julie Zissimopoulos, PhD

Policy Solutions for Earlier Detection of Alzheimer's Disease

Alzheimer's & Dementia

How Novel Imaging Modalities Can Improve Management of Metastatic CRC

SNMMI 2025

Lou Portero

Global Study Links Heavy Alcohol Consumption to Increased Pancreatic Cancer Risk

Pancreatic Cancer

Latest News

A study compared a novel FAP inhibitor PET tracer vs standard-of-care imaging for metastatic colorectal cancer. 

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe